Abbott's TriClip device in the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints for reduction of tricuspid regurgitation.

Abbott announced new data that suggest Abbott's investigational TriClip device may offer physicians an effective minimally invasive repair option for patients suffering from a leaky tricuspid valve , a condition also known as tricuspid regurgitation (TR). For patients suffering from moderate to severe TR, the new data found treatment with TriClip was safe and associated with strong clinical improvement at six-months, including a reduction in TR and improvement in quality of life.

The data was presented earlier at the 31st Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in San Francisco ( September 25 -29 ). The results build upon the initial 30 day data from the TRILUMINATE Feasibility Study, which suggested the promise of TriClip in treating people suffering from this difficult-to-manage structural heart disease.

The tricuspid valve is located between the two chambers on the right side of the heart and is challenging to treat because of its location. A leaky tricuspid valve is a result of the valve's three leaflets not closing properly, and in severe cases this leaking can result in long-term complications such as atrial fibrillation, heart failure and, ultimately, death. Despite advancements in catheter-based devices for treating aortic and mitral valve disease, there are currently no commercially approved minimally invasive devices on the market to treat a leaky tricuspid valve, leaving few options available to patients with moderate to severe TR who are at high risk of experiencing complications with open-heart surgery.

After six months, the TRILUMINATE Feasibility Study showed patients who received Abbott's TriClip device saw a number of benefits, including: Reduction of tricuspid regurgitation. Within the study, 87% of patients had a reduction in their TR at 6 months, with 57% of patients implanted having a TR classification of moderate or better vs. only 6% of patients with the same classification at the time of enrollment. Symptom improvement. Patients receiving TriClip had reduction in their symptoms, with 87% of patients implanted with TriClip being classified as NYHA functional class I/II at six months vs. only 25% of patients receiving the same classification at the time of enrollment. (NYHA is a classification of functional limitations resulting from cardiac disease.) Quality of life improvements. Patients receiving TriClip showed improved KCCQ (Kansas City Cardiomyopathy Questionnaire) scores and a reduction in symptoms that are associated with a reduced burden of their clinical condition and improved physical output.